Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: 200302632, 2004; 10.1373/clinchem.2003.026328
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2003.026328v1
50/3/626    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carnevale, V.
Right arrow Articles by Minisola, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carnevale, V.
Right arrow Articles by Minisola, S.

Received on August 25, 2003
Accepted on December 12, 2003

Endocrinology and Metabolism

Potential Clinical Utility of a New IRMA for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism

Vincenzo Carnevale 1, Simona Dionisi 2, Italo Nofroni 3, Elisabetta Romagnoli 2, Federica Paglia 2, Simona De Geronimo 2, Jessica Pepe 2, Giovanni Clemente 2, Gianfranco Tonnarini 2, Salvatore Minisola 2*

1 Department of Internal Medicine, "Casa Sollievo della Sofferenza" Hospital, IRCCS, Viale dei Cappuccini, San Giovanni Rotondo (FG), Italy
2 Department of Clinical Sciences, University of Rome "La Sapienza", Rome, Italy
3 Department of Experimental Medicine and Clinical Pathology, University of Rome "La Sapienza", Rome, Italy

* To whom correspondence should be addressed. E-mail: salvatore.minisola{at}libero.it.

Background: A new commercially available (so-called second-generation) IRMA for parathyroid hormone (PTH) separately detects intact PTH and its N-truncated fragments; however, no studies have compared the first- and second-generation IRMAs for PTH in patients with primary hyperparathyroidism (PHPT) to assess their respective diagnostic accuracies.

Methods: We concomitantly investigated 39 postmenopausal patients with PHPT and a control group of 70 healthy postmenopausal women matched for age, renal function, and vitamin D status. In all individuals, PTH was measured with a classic IRMA (PTH-S; DiaSorin Inc.), which uses antibodies directed against epitopes 1-34 and 39-84, and a new method (Scantibodies Laboratory. Inc.), which uses antibodies against epitopes 1-4 and 39-84 (PTH-W) and epitopes 7-34 and 39-84 (PTH-T). We also assayed serum PTH in 10 PHPT patients every 24 h for 5 days after successful surgery.

Results: The different assays gave serum PTH values that were >2 SD higher than values for the control population in 59% (PTH-S), 77% (PTH-W), and 82% (PTH-T) of patients with PHPT. However, ROC curve analysis showed no significant differences among the three PTH assays, demonstrating overlapping diagnostic sensitivities. In PHPT patients, the correlation among the assays was highly significant (r = 0.91-0.92; P <0.001). The ratio PTH-W:PTH-T x 100 showed a gaussian distribution in both PHPT patients and controls, whose mean (SD) values [63.4 (13.3)% vs 64.5 (9.5)%, respectively] did not differ significantly. After parathyroidectomy, the mean percentages of variation in PTH detected with all of the assays were quite similar.

Conclusions: The distribution of the PTH-W:PTH-T ratio in patients and controls suggests that PHPT does not markedly influence the rate at which biologically inactive fragments are generated by central or peripheral cleavage of PTH. The similar postoperative curves seem to contradict the hypothesized effect of acute hypocalcemia in modulating the central secretion of hormonal fragments. Our results indicate that the three investigated assays have similar diagnostic sensitivities in PHPT.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Clin. Endocrinol. Metab.Home page
R. Eastell, A. Arnold, M. L. Brandi, E. M. Brown, P. D'Amour, D. A. Hanley, D. S. Rao, M. R. Rubin, D. Goltzman, S. J. Silverberg, et al.
Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop
J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 340 - 350.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. L. Serra, R. Savoca, A. R. Huber, U. Hepp, A. Delsignore, M. Hersberger, and R. P. Wuthrich
Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 577 - 583.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. Boudou, F. Ibrahim, C. Cormier, E. Sarfati, and J.-C. Souberbielle
Unexpected Serum Parathyroid Hormone Profiles in Some Patients with Primary Hyperparathyroidism
Clin. Chem., April 1, 2006; 52(4): 757 - 760.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Boudou, F. Ibrahim, C. Cormier, A. Chabas, E. Sarfati, and J.-C. Souberbielle
Third- or Second-Generation Parathyroid Hormone Assays: A Remaining Debate in the Diagnosis of Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6370 - 6372.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J.-C. Souberbielle, V. Fayol, C. Sault, E. Lawson-Body, A. Kahan, and C. Cormier
Assay-Specific Decision Limits for Two New Automated Parathyroid Hormone and 25-Hydroxyvitamin D Assays
Clin. Chem., February 1, 2005; 51(2): 395 - 400.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the American Association for Clinical Chemistry.